Literature DB >> 9185147

Disequilibria in the distribution of rpoB alleles in rifampicin-resistant M. tuberculosis isolates from Germany and Sierra Leone.

H Rinder1, P Dobner, K Feldmann, M Rifai, G Bretzel, S Rüsch-Gerdes, T Löscher.   

Abstract

The effectiveness of culture-independent resistance predictions by molecular techniques is dependent on the number and the frequency of accessible resistance-associated genomic mutations. We have characterized an rpoB gene region involved in rifampicin resistance in 49 Mycobacterium tuberculosis isolates resistant to rifampicin from Germany and Sierra Leone. The determined frequencies of mutations differed between both countries of origins as well as with respect to previously reported distributions of resistance mutations. It is concluded that at least for some isolates the acquisition of mutations leading to rifampicin resistance in clinical samples of M. tuberculosis is a non-random process which may lead to a geographical and temporal dependence of the sensitivities of molecular typing techniques for rifampicin resistance predictions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9185147     DOI: 10.1089/mdr.1997.3.195

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  9 in total

1.  rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy.

Authors:  G Pozzi; M Meloni; E Iona; G Orrù; O F Thoresen; M L Ricci; M R Oggioni; L Fattorini; G Orefici
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

2.  Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay.

Authors:  Z Bártfai; A Somoskövi; C Ködmön; N Szabó; E Puskás; L Kosztolányi; E Faragó; J Mester; L M Parsons; M Salfinger
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

3.  Disequilibrium in distribution of resistance mutations among Mycobacterium tuberculosis Beijing and non-Beijing strains isolated from patients in Germany.

Authors:  Doris Hillemann; Tanja Kubica; Sabine Rüsch-Gerdes; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Use of DNA extracts from Ziehl-Neelsen-stained slides for molecular detection of rifampin resistance and spoligotyping of Mycobacterium tuberculosis.

Authors:  A G M Van Der Zanden; E M Te Koppele-Vije; N Vijaya Bhanu; D Van Soolingen; L M Schouls
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

5.  Characterization of spontaneous, In vitro-selected, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37Rv.

Authors:  G P Morlock; B B Plikaytis; J T Crawford
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

6.  Development of multiplex assay for rapid characterization of Mycobacterium tuberculosis.

Authors:  I L Bergval; R N C P Vijzelaar; E R Dalla Costa; A R J Schuitema; L Oskam; A L Kritski; P R Klatser; R M Anthony
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

7.  Pre-existing isoniazid resistance, but not the genotype of Mycobacterium tuberculosis drives rifampicin resistance codon preference in vitro.

Authors:  Indra Bergval; Brian Kwok; Anja Schuitema; Kristin Kremer; Dick van Soolingen; Paul Klatser; Richard Anthony
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

8.  Drug resistance mutations and heteroresistance detected using the GenoType MTBDRplus assay and their implication for treatment outcomes in patients from Mumbai, India.

Authors:  Monica Prem Tolani; Desiree Therese Blossom D'souza; Nerges Furdoon Mistry
Journal:  BMC Infect Dis       Date:  2012-01-20       Impact factor: 3.090

9.  Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance.

Authors:  Indra L Bergval; Anja R J Schuitema; Paul R Klatser; Richard M Anthony
Journal:  J Antimicrob Chemother       Date:  2009-07-04       Impact factor: 5.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.